ERYTECH Pharma to partner with Teva for long term distribution agreement in Israel Post author:admERY Post published:May 17, 2011 Post category:Newsroom ERYTECH Pharma is pleased to announce it has signed an exclusive long term agreement with Teva for the registration, marketing, distribution and sale of Graspa®, the company‟s lead product, in Israel. You Might Also Like ERYTECH announces its IPO on NYSE Euronext Paris regulated market April 18, 2013 ERYTECH Presents New Preclinical Data on ERY-MET at the 2017 ASCO GI Symposium January 17, 2017 ERYTECH Reports Third Quarter 2018 Financial Results and Provides Business Update November 12, 2018